Phase II trial of Survivin-responsive conditionally replicating adenovirus (Surv.m-CRA-1) by repeated local administration in patients with advanced primary malignant bone tumor. - SURV-B-study
100 项与 Surv BioPharma, Inc. 相关的临床结果
0 项与 Surv BioPharma, Inc. 相关的专利(医药)
100 项与 Surv BioPharma, Inc. 相关的药物交易
100 项与 Surv BioPharma, Inc. 相关的转化医学